

PRESS RELEASE

ADVENTA Berhad (618533-M)

For Immediate Release

(Petaling Jaya, Selangor, 28 Feb 2019)

Adventa Berhad (“Adventa”) today announced the financial results for the 14 months period ended 31 Dec 2018. The full year loss of RM 27.4 m reflected a large impairment of assets in one of its subsidiary companies.

The result is not as it seems. The impairment is the prudent approach that implies the less-than-certainty view, at this juncture of time, of the subsidiary’s ability to recover what was invested in the research, and subsequent development of equipment and related products for the treatment of renal dialysis at home. Although the cycle life of the products and equipment remain relatively unchanged and the technology derived from the research and development has enabled new product designs, the Board prefers that its assets are conservatively valued and not speculative.

Since Adventa invested in the business of home-based dialysis, it has seen unprecedented success and acceptance by patients, caregivers and doctors. Being a responsible company, we have subjected all the medical equipment and medical consumables to exhaustive time-based tests and field clinical trials, involving many operation scenarios, diversity of users and across all corners of the country. Those equipment and products have shown to be able to deliver a comprehensive and safe treatment to patients from urban Kuala Lumpur to longhouses in Sarawak. Never was there a program that delivered such improved quality of life and satisfaction to dialysis patients.

This program is now being evaluated overseas and in various stages of registration and approvals. As any dialysis program in Asia, home-based treatment is almost always funded by the government or agencies of the government. Hence adoption and implementation take time.

The potential of this business is indisputable. The success may be measured by time or monetary gains or events, making it subjective for near future valuations when the program is still in its infancy in various new markets. However, as the markets are established with time, clearing the hurdles of registrations and approvals, there is no denying of the huge commercial potential of this business.

As directors, we urge our shareholders to understand the dialysis business, its simplicity in strategy and the complexities of program implementation. We strongly believe in the viability, value and great opportunity that it offers the company to realize its bold investments in medical science that changes the way medical treatments are traditionally done. Your investment in the future of medical technology is with Adventa.

Adventa invests in new healthcare and industrial applied technologies with potential of global scale.
The company is driven by passion and people who believe in the future of technology.